Bibliography
- HILLEMAN MR: Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine (2000) 18(15):1436–1447.
- NO AUTHORS LISTED: Achievements in public health, 1990-1999: impact of vaccines universally recommended for children. Morb. Mortal. Wkly Rep. (1999) 48:243–248.
- TRIGG PI, KONDRACHINE AV: The current global malaria situation. In: Malaria: Parasite Biology, Pathogenesis and Protection. Sherman IW (Ed.), ASM Press,Washington DC, USA (1998):11–22.
- MOORTHY VS, GOOD ME HILL AV: Malaria vaccine developments. Lancet (2004) 363(9403):150–156.
- ••A recent review on malaria vaccinedevelopment, with highlights on thecandidate vaccine antigens that have reached clinical trials.
- GILLES HM: The malaria parasites. In: Bruce-Chwatt's Essential Malariology Gilles HM, Warrell DA (Ms), Edward Arnold, London, UK (1993):12–34.
- WEBSTER D, HILL AV: Progress with new malaria vaccines. Bull. World Health Organ. (2003) 81(12):902–909.
- WEBSTER DE, GAHAN ME, STRUGNELL RA, WESSELINGH SW: Advances in oral vaccine delivery options: what is on the horizon? Am. I Drug Deify. (2003) 1(4):227–240.
- OGRA PL, FADEN H, WELLIVER RC: Vaccination strategies for mucosal immune responses. Clin. Microbiol Rev (2001) 14(2):430–445.
- •A comprehensive review onvaccination strategies for induction of mucosal immunity.
- WANG L, KEDZIERSKI L,WESSELINGH SL, COPPEL RL: Oral immunization with a recombinant malariaprotein induces conformational antibodies and protects mice against lethal malaria. Infect. Immun. (2003) 71(5):2356–2364.
- ••The first demonstration that oraladministration of recombinant Plasmodium proteins can provide protection against malaria.
- KEDZIERSKI L, BLACK CG,COPPEL RL: Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect. Immun. (2000) 68(10):6034–6037.
- WANG L, GOSCHNICK M,COPPEL RL: Oral immunisation with a combination of Plasmodium yoebimerozoite surface protein 1 and 4/5 enhances protection against lethal malaria challenge. Infect. Immun. (2004) (In Press).
- LEWIS AP: Cloning and analysis of the gene encoding the 230-kilodalton merozoite surface antigen of Plasmodium yoebi MM. Biochem. Parasitol (1989) 36(3):271–282.
- KEDZIERSKI L, BLACK C, COPPEL RL: Characterisation of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii. Mol Biochem. Parasitol (2000) 105(1):137–147.
- MARSHALL VM, SILVA A, FOLEY M et al.: A second merozoite surface protein (MSP-4) of Plasmodium fakiparum that contains an epidermal growth factor-like domain. Infect. Immun. (1997) 65(11):4460–4467.
- MEDINA E, GUZMAN CA: Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine (2001) 19(13-14):1573–1580.
- •This review summarises the vaccine delivery systems based on live bacterial vectors, and discusses their potential and limitations.
- GARMORY HS, BROWN KA,TITBALL RW: Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev (2002) 26(4)339–353.
- TACKET CO, SZTEIN MB, LOSONSKY GA et al.: Safety of live oral Salmonella Ophivaccine strains with deletions in htrA and aroC aroD and immune response in humans. aInfect. Inman. (1997) 65(2):452–456.
- TACKET CO, SZTEIN MB, WASSERMAN SS et al: Phase II clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect. Inman. (2000) 68(3):1196–1201.
- TACKET CO, GALEN J, SZTEIN MB et al.: Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol (2000) 97(2):146–153.
- MASTROENI P, CHABALGOITY JA, DUNSTAN SJ, MASKELL DJ, DOUGAN G: Salmonella: immune responses and vaccines. Vet. (2001) 161(2):132–164.
- BUMANN D, HUECK C,AEBISCHER T, MEYER TF: Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Iinmunol. Med. Microbiol (2000) 27(4):357–364.
- HOFFMAN SL, FRANKE ED, HOLLINGDALE MR, DRUILHE P: Attacking the infected hepatocyte. In: Malaria Vaccine Development: A Multi-Immune Response Approach.Hoffman SL (Ed.), ASM Press, Washington DC, USA (1996):35–76.
- SAD OFF JC, BALLOU WR, BARON LSet al: Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science (1988) 240(4850):336–338.
- •The first demonstration that oral immunisation with attenuated recombinant Salmonella can induce protective immunity against malaria infection.
- AGGARWAL A, KUMAR S, JAFFE R et al.: Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. Exp. Med. (1990) 172(4):1083–1090.
- FLYNN JL, WEISS WR, NORRIS KA et al: Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Ma Microbiol (1990) 4(12):2111–2118.
- RUIZ-PEREZ F, LEON-KEMPIS R, SANTIAGO-MACHUCA A et al.: Expression of the Plasmodium fakiparum immunodominant epitope (NANP) (4) on the surface of Salmonella enterica using the autotransporter MisL. Infect. Immun. (2002) 70(7):3611–3620.
- GONZALEZ C, HONE D,NORIEGA FR et al: Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium fakiparum: strain construction and safety and immunogenicity in humans. I Infect. Dis. (1994) 169(4):927–931.
- HOLDER AA: Preventing merozoite invasion of erythrocytes. In: Malaria Vaccine Development: A Multi-Immune Response Approach. Hoffman SL (Ed.), ASM Press, Washington DC, USA (1996):77–104.
- TOEBE CS, CLEMENTS JD, CARDENAS L, JENNINGS GJ,WISER MF: Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1. Am. I Trop. Med. Hyg. (1997) 56(2):192–199.
- CRISANTI A, MULLER HM,HILBICH C et al.: Epitopes recognized by human T cells map within the conserved part of the GP190 of I? fakiparum. Science (1988) 240(4857):1324–1326.
- GOMEZ-DUARTE OG, PASETTI ME SANTIAGO A et al: Expression, extracellular secretion, and immunogenicity of the Plasmodium fakiparum sporozoite surface protein 2 in Salmonella vaccinestrains. Infect. Immun. (2001)69(2):1192–1198.
- SCHORR J, KNAPP B, HUNDT E, KUPPER HA, AMANN E: Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine (1991) 9(9):675–681.
- HADDAD D, LILJEQVIST S, KUMAR S et al.: Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med. Microbiol (1995) 12(3-4):175–186.
- SOMNER EA, OGUN SA, SINHA KA et al.: Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains. Microbiology(1999) 145(Pt 1):221–229.
- WU S, BEIER M, SZTEIN MB et al: Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium fakiparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C. Biotechnol (2000) 83(1-2):125–135.
- GOMEZ-DUARTE OG, GALEN J, CHATFIELD SN et al.: Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. Vaccine (1995) 13(16):1596–1602.
- CARDENAS L, CLEMENTS JD: Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine (1993) 11(2):126–135.
- STRUGNELL RA, MASKELL D, FAIRWEATHER N et al: Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene (1990) 88(1):57–63.
- DUNSTAN SJ, SIMMONS CP,STRUGNELL RA: Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium. Infect. Immun. (1999) 67(10):5133–5141.
- QIAN F, PAN W: Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium fakiparum for applications in human vaccine production. Infect. Immun. (2002) 70(4):2029–2038.
- ATTRIDGE SR, DAVIES R,LABROOY JT: Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine (1997) 15(2):155–162.
- SIZEMORE DR, BRANSTROM AA, SAD OFF JC: Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (1995) 270(5234):299–302.
- WEISS S, CHAKRABORTY T: Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. CLIFF. Opin. Biotechnol (2001) 12(5):467–472.
- DIETRICH G, GENTSCHEV I, HESS J et al: Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol Today (1999) 20(6):251–253.
- KUMAR S, EPSTEIN JE, RICHIE TL et al: A multilateral effort to develop DNA vaccines against fakiparum malaria. Trends Parasitol (2002) 18(3):129–135.
- O'HAGAN DT: Mietopattieles and polymers for the mucosal delivery of vaccines. Adv. Drug Deify. Rev (1998) 34(2–3):305-320.
- ZHO F, NEUTRA MR: Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci. Rep. (2002) 22(2):355–369.
- MOWAT AM, SMITH RE,DONACHIE AM et al: Oral vaccination with immune stimulating complexes. Immunol Lett. (1999) 65(1-2):133–140.
- KANEDA Y: Virosomes: evolution of the liposome as a targeted drug delivery system. Adv. Drug Deify. Rev (2000) 43(2-3):197–205.
- PUMPENS P, GRENS E: HBV core particles as a carrier for B cell/T cell epitopes. Intervirology (2001) 44(2-3):98–114.
- TURPEN TH, REINL SJ,CHAROENVIT Y et al.: Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology (1995) 13(1):53–57.
- YASAWARDENE SG,LOMONOSS OFF GP, RAMASAMY R: Expression & immunogenicity of malaria merozoite peptides displayed on the small coat protein of chimaeric cowpea mosaic virus. Indian J. Med. Res. (2003) 118:115–124.
- KATZ DE, DELORIMIER AJ, WOLF MK et al.: Oral immunization ofadult volunteers with microencapsulated enterotcodgenic Escherichia coil (ETEC) C56 antigen. Vaccine (2003) 21(5-6):341–346.
- TACKET CO, REID RH, BOEDEKER EC et al.: Enteral immunization and challenge of volunteers given enterotoxigenic E coil CFA/II encapsulated in biodegradable microspheres. Vaccine (1994) 12(14):1270–1274.
- BALL JM, GRAHAM DY, OPEKUN AR et al.: Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology (1999) 117(1):40–48.
- KAPUSTA J, MODELSKA A,FIGLEROWICZ M et al: A plant-derivededible vaccine against hepatitis B virus. FASEB J. (1999) 13(13):1796–1799.
- TACKET CO, SZTEIN MB, LOSONSKY GA, WASSERMAN SS, ESTES MK: Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.Clin. Immunol (2003) 108(3):241–247.
- CHAICUMPA W,CHONGSA-NGUAN M,KALAMBAHETI T et al: Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. Vaccine (1998) 16(7):678–684.
- CHILDERS NK, MICHALEK SM, PRITCHARD DG, MCGHEE JR: Mucosal and systemic responses to an oral liposome-Streptococcus mutans carbohydrate vaccine in humans. Reg. Immunol (1990) 3(6):289–296.
- JONES DH, CORRIS S, MCDONALD S, CLEGG JC, FARRAR GH: Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine (1997) 15(8):814–817.
- KANEKO H, BEDNAREK I, WIERZBICKI A et al.: Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology (2000) 267(1):8–16.
- SHI W, LIU J, HUANG Y, QIAO L: Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. Vim]. (2001) 75(21):10139–10148.
- CARCABOSO AM, HERNANDEZ RIVI, IGARTUA M et al: Immune response afteroral administration of the encapsulatedmalaria synthetic peptide SP(66. Lit. J. Pharm. (2003) 260(2):273–282.This paper describes the oral administration of the synthetic peptide SPF66 encapsulated in PLGA to mice. Immune responses were comparable to those obtained with systemic immunisation in several clinical trials.
- AWRAM P, GARDNER RC, FORSTER RL, BELLAMY AR: The potential of plant viral vectors and transgenic plants for subunit vaccine production. Adv. Virus Res. (2002) 58:81–124.
- DANIELL H, STREATFIELD SJ, WYCOFF K: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. (2001) 6(5):219–226.
- MA JK, DRAKE PM, CHRISTOU P: The production of recombinant pharmaceutical proteins in plants. Nat. Rev Genet. (2003) 4(10):794–805.
- •A comprehensive review on the application of transgenic plants for the production of vaccine antigens as well as other bioparmaceuticals.
- LAMPHEAR BJ, STREATFIELD SJ, JILKA JM et al.: Delivery of subunit vaccines in maize seed. J. Control. Release (2002) 85(1-3):169–180.
- DE COSA B, MOAR W, LEE SB, MILLER M, DANIELL H: Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat. Biotechnol (2001) 19(1):71–74.
- YU J, LANGRIDGE WH: A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol (2001) 19(6):548–552.
- YE X, AL-BABILI S, KLOTI A et al.: Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 287(5451):303–305.
- TACKET CO, MASON HS, LOSONSKY G et al.: Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. (2000) 182(1):302–305.
- TACKET CO, MASON HS,LOSONSKY G et al.: Immunogenicity in humans of a recombinant bacterial antigen delivered in a trangenic potato. Nat. Med. (1998) 4(5):607–609.
- YUSIBOV V, HOOPER DC, SPITSIN SV et al.: Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine (2002) 20(25-26):3155–3164.
- GHOSH S, MALHOTRA P,LALITHA PV, GUHA-MUKHERJEE S, CHAUHAN VS: Expression of Plasmodium falcipamm C-terminal region of merozoite surface protein (PfMSP119), a potential malaria vaccine candidate, in tobacco. Plant Science (2002) 162:335–343.
- WANG L, CAMPBELL A, WEBSTER D et al.: Feasibility of using transgenic plants to induce protective immunity against malaria. Exp. Parasitol (2003) 105(1):52.
- KAPUSTA J, MODELSKA A,PNIEWSKI T et al.: Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv. Exp. Med. Biol. (2001) 495:299–303.
- •This paper shows that humans may be immunised orally against hepatitis B virus with lettuce plants expressing the viral antigen. This study provides an example for the use of plant-based vaccines against non-enteric pathogens.
- KONG Q, RICHTER L, YANG YF et al: Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA (2001) 98(20):11539–11544.
- RICHTER LJ, THANAVALA Y, ARNTZEN CJ, MASON HS:Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol (2000) 18(11):1167–1171.
- HAQ TA, MASON HS, CLEMENTS JD, ARNTZEN CJ: Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 268(5211):714–716.
- GARDNER MI, HALL N, FUNG E et al: Genome sequence of the human malaria parasite Plasmodium fakiparum. Nature (2002) 419(6906):498–511.
- PAN W, RAVOT E, TOLLE R et al: Vaccine candidate MSP-1 from Plasmodium falcipamm: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia cob and mammalian cells. Nucleic Acids Res. (1999) 27(4):1094–1103.
- DANIELL H, LEE SB, PANCHAL T, WIEBE PO: Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenictobacco chloroplasts. Ma Biol. (2001) 311(5):1001–1009.
- DANIELL H, KHAN MS, ALLISON L: Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci. (2002) 7(2):84–91.
- •This review summarises the application of chloroplast transformation on vaccine production in plants, with highlights on its potential for multigene engineering and high-level transgene expression.
- HATHAWAY LJ, KRAEHENBUHL JP: The role of M cells in mucosal immunity. Cell. Ma Life Sri. (2000) 57(2):323–332.
- ALTARE F, LAMMAS D, REVY P et al: Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. Clin. Invest. (1998) 102(12):2035–2040.
- DE JONG R, ALTARE F, HAAGEN IA et al: Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science (1998) 280(5368):1435–1438.
- RIGANO MM, ALVAREZ ML, PINKHASOV J et al.: Production of a fusion protein consisting of the enterotwdgenic Escherichia cob heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep. (2004) 22(7):502–508.
- CHEN H, TORCHILIN V, LANGER R: Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. (1996) 13(9):1378–1383.
- RESCIGNO M: Identification of a new mechanism for bacterial uptake at mucosal surfaces, which is mediated by dendritic cells. Pathol Biol. (Paris) (2003) 51(2):69–70.
- WIERZBICKI A, KISZKA I, KANEKO H et al: Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine (2002) 20(9-10):1295–1307.
- STROBEL S, MOWAT AM: Immune responses to dietary antigens: oral tolerance. Immunol Today (1998) 19(4):173–181.
- BLANAS E, CARBONE FR, ALLISON J, MILLER IF, HEATH WR: Induction of autoimmune diabetes by oral administration of autoantigen. Science (1996) 274(5293):1707–1709.
- WIENDL H, HOHLFELD R: Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs (2002) 16(3):183–200.
- ELSON CO, EALDING W: Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. Immunol (1984) 133(6):2892–2897.
- PLANT A, WILLIAMS R, JACKSON ME, WILLIAMS NA: The B subunit of Escherichia cob heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2-type immune responses. Eur. Immunol (2003) 33(11):3186–3195.
- KAPIKIAN AZ: A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found. Symp. (2001) 238:153-171; discussion 171–159.
- PETER G, MYERS MG: Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics (2002) 110(6):e67.
- QADRI F, AHMED T, AHMED F et al: Safety and immunogenicity of an oral, inactivated enterotwdgenic Escherichia cob plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine (2003) 21(19-20):2394–2403.
- KOTLOFF KL, TAYLOR DN,SZTEIN MB et al.: Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect. Immun. (2002) 70(4):2016–2021.
- JIRATHITIKAL V, SOOKSATHAN P, METADILOGKUL 0,BOURINBAIAR AS: V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential. Vaccine (2003) 21(7-8):624–628.
- GOOD MF, DOOLAN DL: Immune effector mechanisms in malaria. Can: Opin. Immunol (1999) 11(4):412–419.
- ••A review outlining theimmune mechanisms against the pre-erythrocytic, asexual erythrocytic and sexual stages of Plasmodium.
- AGNIESZKA AE, WANG L, BLACK CG, COPPEL RU: Merozoite cell biology. In: Malaria Parasites: Cenomes and Molecular Biology Waters AP, Janse CJ (Eds), Caister Academic Press, Wymondham, UK (2004):365–444.
- KASLOW DC, QUAKYI IA, SYIN C et al: A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature (1988) 333(6168):74–76.
- DUFFY PE, KASLOW DC: A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as fakiparum malaria transmission-blocking vaccines. Infect. Inman. (1997) 65(3):1109–1113.